Duloxetine: a review

References

• Danish University Antidepressant Group. Citalopram, clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology90, 131–138 (1986).
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Paroxetine: a selective serotonin re-uptake inhibitor showing better tolerance but weaker antidepressanteffect than clomipramine in a controlled multicenter study. I Affect. Disord. 18,289–299 (1990).
   PubMed Web of Science ®Google Scholar
• Thase EA, Ensuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin re-uptake inhibitors. Br. Psychiatry 178,234–241 (2001).
   Google Scholar
• Schatzberg AF, Kremer C, Rodrigues HE, Murphy Jr GM, The Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. A117. I Ceriatr fiychiatry10, 541–550 (2002).
   Google Scholar
• Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J. Clin. Psychiatry 60\(Suppl. 22), 7–11 (1999).
   Google Scholar
• Clerc G. Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline re-uptake inhibitor: a comparison with fluvoxamine. Int. Clin. P9rhopharmacol 16,145–151 (2001).
   Google Scholar
• Kasamo K, Blier P, De Montigny C. Blockade of the serotonin and noradrenaline uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. .1. Phatmacol Exp. flier. 277, 278–286 (1996).
   Google Scholar
• Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine urinary incontinence study group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am. j Obstet. Cynecol 187, 40–48 (2002).
   PubMed Web of Science ®Google Scholar
• Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P Assessment of the serotonin and noradrenaline reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24,511-521 (2001). toSharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual serotonin and noradrenaline reuptake inhibitor. J. Clin. Pharmacol 40, 161–167 (2000).
   Google Scholar
• Berk M, Du Plessis AD, Birkett M, Richardt D. An open label study of Duloxetine Hydrochloride, a mixed 5-HT and noradrenaline re-uptake inhibitor, in patients with Major Depressive disorder. Int. Clin. P9rhopharmacol 12,137–140 (1997).
   Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. j Clin. Psychiatry63, 225–231 (2002).
   PubMed Web of Science ®Google Scholar
• •A key clinical trial.
   Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine 60mg once daily for major depressive disorder: a randomised double-blind placebo-controlled trial. j Clin. liychiatry63, 308–315 (2002). A key clinical trial.
   Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. Psychiatric Res. 36, 383–390 (2002). A key clinical trial.
   Google Scholar
• Goldstein DJ, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack M. Duloxetine vs. Paroxetine in the treatment of depression. 155th Annual Meeting of the American P9rhiatric Association, PA, USA (2002).
   Google Scholar
• Goldstein DJ, Detke M, Lu Y, Mallinckrodt C, Demitrack M. The antidepressant Duloxetine reduces anxiety symptom severity. 155th Annual Meeting of the American Psychiatric Association, PA, USA (2002).
   Google Scholar
• Tran P, Lu Y, Detke M eta] Evaluation of duloxetine in the treatment of depression. 155th Annual Meeting of the American Psychiatric Association, PA, USA (2002).
   Google Scholar
• Tran P, Lu Y, Detke M, Goldstein D, Mallinckrodt C, Demitrack M. Safety and tolerability of the antidepressant duloxetine. 155th Annual Meeting- of the American P9rhiatric Association, PA, USA (2002).
   Google Scholar
• Kirmayer U, Robbins JM, Dworkind M et al Somatisation and the recognition of depression and anxiety in primary care. Am. P9rhiatry150,734–741 (1993).
   Google Scholar
• Stahl SM. The psychopharmacology of painful physical symptoms in depression. Clin. Psychiab y63, 382–383 (2002).
   PubMed Web of Science ®Google Scholar
• Fava M. Somatic symptoms, depression and antidepressant treatment. j Clin. PTchiaby 63,305–307 (2002).
   PubMed Web of Science ®Google Scholar
• Lynch M. Antidepressants as analgesics: a review of randomised controlled trials. Psychiatry Neurosci. 26,30–36 (2001).
   PubMed Web of Science ®Google Scholar
• Mallinckrodt C, Wiltse C, Tran P, Detke M, Panagallo B, Goldstein M. Minimal effect of the antidepressant Duloxetine on weight. 155th Annual Meeting- of the American fiychiatric Association, PA, USA (2002).
   Google Scholar
• Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes. Rev 1,127–139 (2000).
   PubMedGoogle Scholar
• O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess. 6,1–97 (2002).
   PubMedGoogle Scholar
• Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance and public health significance of subthreshold depressions. Bychiatr Clin. North Am. 25, 685–698 (2002).
   Google Scholar
• Tran PV, Bymaster FP, McNamara RK, Potter WZ. Dual monoamine modulation for improved treatment of major depressive disorder. J. Gun. Psychopharmacol 23, 78–86 (2003).
   Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Bowers MB et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 48, 303–307 (1991).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad U, Threlkeld PG et al Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in Otto and in Om, human serotonin receptor subtypes and other neuronal systems. Neuropsychophannacology25, 871–879 (2001).
   PubMed Web of Science ®Google Scholar
• •A key paper on the mechanism of action of duloxetine.
   Google Scholar